Nothing Special   »   [go: up one dir, main page]

TR201905612T4 - Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları. - Google Patents

Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları. Download PDF

Info

Publication number
TR201905612T4
TR201905612T4 TR2019/05612T TR201905612T TR201905612T4 TR 201905612 T4 TR201905612 T4 TR 201905612T4 TR 2019/05612 T TR2019/05612 T TR 2019/05612T TR 201905612 T TR201905612 T TR 201905612T TR 201905612 T4 TR201905612 T4 TR 201905612T4
Authority
TR
Turkey
Prior art keywords
conjugates
polyvalent
proteins
cell
cell penetrating
Prior art date
Application number
TR2019/05612T
Other languages
English (en)
Inventor
Strieker Matthias
Mier Walter
Haberkorn Uwe
Original Assignee
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Heidelberg Ruprecht Karls filed Critical Univ Heidelberg Ruprecht Karls
Publication of TR201905612T4 publication Critical patent/TR201905612T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş, bir protein ve çok değerlikli, hücreye nüfuz eden peptidi/peptitleri içeren konjugatlar ile ilgili olup, her bir çok değerlikli, hücreye nüfuz eden peptit, en az iki adet hücreye nüfuz eden peptidi içerir, burada çok değerlikli, hücreye nüfuz eden peptit(ler), proteine kovalent olarak bağlıdır. Mevcut buluş ayrıca konjugatları üretme yöntemi ve bunların tıbbi kullanımları, özellikle bunların hastalıkların tanısı, önlenmesi ve/veya tedavisinde kullanımı ile ilgilidir. Mevcut buluş, buluşun konjugatlarının bir hastaya uygulanmasını içeren, hastalıkların tanısı, önlenmesi ve/veya tedavisine ilişkin yöntemler ile ilgilidir.
TR2019/05612T 2012-12-05 2013-12-04 Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları. TR201905612T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261733619P 2012-12-05 2012-12-05

Publications (1)

Publication Number Publication Date
TR201905612T4 true TR201905612T4 (tr) 2019-05-21

Family

ID=49726754

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05612T TR201905612T4 (tr) 2012-12-05 2013-12-04 Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları.

Country Status (5)

Country Link
US (1) US10253099B2 (tr)
EP (1) EP2928502B1 (tr)
ES (1) ES2722924T3 (tr)
TR (1) TR201905612T4 (tr)
WO (1) WO2014086835A1 (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615049B1 (pt) 2005-08-24 2023-04-25 Immunogen, Inc Processo para a preparação de um conjugado de anticorpo- maitansinóide
EP3480202A1 (en) 2009-06-03 2019-05-08 ImmunoGen, Inc. Conjugation methods
CN103717262B (zh) * 2011-03-29 2017-09-15 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
SG10201702737TA (en) 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US9745421B2 (en) * 2013-03-20 2017-08-29 The Regents Of The University Of California Dendronized polymers for nucleic acid delivery
US9492544B2 (en) * 2013-04-11 2016-11-15 Vanderbilt University Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
US10287331B2 (en) 2013-04-15 2019-05-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Mitochondrial proteins constructs and uses thereof
WO2015162287A1 (en) * 2014-04-25 2015-10-29 Phi Pharma Sa Keratan sulfate specific transporter molecules
US20220241426A1 (en) * 2014-08-14 2022-08-04 Friedrich-Schiller-Universitaet Jena Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects
EP3031820A1 (en) 2014-12-08 2016-06-15 Life Science Inkubator JC Polyomavirus VLP (virus-like particle) with a targeting peptide
IL302965A (en) * 2015-05-29 2023-07-01 Univ Pennsylvania Preparations and methods for reducing unfolded proteins
CN112263683A (zh) 2015-08-11 2021-01-26 同宜医药（苏州）有限公司 多配体药物偶联体及其用途
WO2017101786A1 (zh) * 2015-12-14 2017-06-22 韩苏 一种多肽化合物及其制备方法与应用
WO2017160662A1 (en) 2016-03-12 2017-09-21 The Regents Of The University Of California Biodegradable vectors for efficient rna delivery
JP6795679B2 (ja) * 2016-04-06 2020-12-02 アイキュア ビーエヌピー カンパニー リミテッド 細胞膜に浸透する能力を有するペプチド
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
US10183080B2 (en) 2016-09-02 2019-01-22 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Use of single dendritic wedge cell penetrating peptides to facilitate cellular delivery of nanoparticles and nanoparticles carrying cargos
EP3538125A4 (en) 2016-11-09 2020-10-07 Ohio State Innovation Foundation DISULPHIDE-BOUND CELL PENETRATION PEPTIDES, THEIR PREPARATION AND USE METHODS
KR101797167B1 (ko) 2016-11-09 2017-11-13 주식회사 바이오셀트란 신규의 프로테인 트랜스덕션 도메인 및 이의 용도
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
US10774122B2 (en) * 2017-03-21 2020-09-15 The Regents Of The University Of Michigan ERG targeted therapy
US11208534B2 (en) 2017-06-26 2021-12-28 The Regents Of The University Of California Dynamic polymers based on silyl ether exchange
EP3688011A4 (en) * 2017-10-25 2021-11-24 The Administrators Of The Tulane Educational Fund PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE
US11447525B2 (en) 2018-05-02 2022-09-20 Niigata University Peptide and use therefor
WO2019217682A1 (en) * 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
US11370889B2 (en) 2018-05-18 2022-06-28 The Regents Of The University Of California Boroxine based dynamic thermosetting polymers
WO2019226785A1 (en) * 2018-05-23 2019-11-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof
US11266603B2 (en) * 2018-06-28 2022-03-08 Academia Sinica Synthetic polypeptides and uses thereof
EP3820885A4 (en) * 2018-07-11 2022-04-20 The Brigham & Women's Hospital, Inc. METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DRUGS ACROSS THE BLOOD-BRAIN BARRIER
CN109553657B (zh) * 2018-11-30 2021-10-19 东北农业大学 一种非完美两亲性肽w4及其制备方法和应用
KR102351041B1 (ko) * 2018-12-19 2022-01-13 한국화학연구원 인간 lrrc24 단백질 유래 세포막 투과 도메인
WO2020130548A1 (ko) * 2018-12-19 2020-06-25 한국화학연구원 인간 쥐피에이티씨에치4 단백질 유래 세포막 투과 도메인
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
IL294608A (en) 2020-01-10 2022-09-01 Brigham & Womens Hospital Inc Methods and compositions for administering immunotherapy agents across the blood-brain barrier for the treatment of brain cancer
KR102484312B1 (ko) * 2020-05-14 2023-01-02 한국화학연구원 고효능 사스 코로나바이러스 2 항원 및 이를 포함하는 백신 조성물
CN113943778A (zh) * 2020-07-17 2022-01-18 通用电气医疗集团股份有限公司 用于核酸检测的分子探针及其制备方法和用途
US20230374471A1 (en) * 2020-10-13 2023-11-23 University Of Florida Research Foundation, Incorporated Self-assembling uricase fusion peptides
CN114573686A (zh) * 2020-11-30 2022-06-03 中国医学科学院药物研究所 含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽及其应用
EP4416282A1 (en) * 2021-10-14 2024-08-21 The University of Queensland Proteinaceous molecules and uses therefor
CN113813364B (zh) * 2021-11-09 2024-06-28 深圳辰扬生物科技有限公司 多肽的抗成瘾及其复发的用途、复合体及多肽
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof
WO2024175780A1 (en) 2023-02-23 2024-08-29 Micropep Technologies S.A. Micropeptides to improve plant immunity and application thereof
CN116808231B (zh) * 2023-07-07 2024-03-26 中国药科大学 一种细胞穿膜肽偶联舒必利前药体系以及制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
WO2006056227A1 (en) * 2004-11-27 2006-06-01 Eberhard-Karls- Universität Tübingen Universitätsklinikum Conjugates comprising the active agent and flanking or branched-chain peptides
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy

Also Published As

Publication number Publication date
EP2928502A1 (en) 2015-10-14
WO2014086835A1 (en) 2014-06-12
US10253099B2 (en) 2019-04-09
US20150297742A1 (en) 2015-10-22
ES2722924T3 (es) 2019-08-20
EP2928502B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
TR201905612T4 (tr) Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları.
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
WO2019094692A3 (en) Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
BR112014006376A2 (pt) terapia baseada em proteínas e diagnóstico de patologia mediada por tau em doença de alzheimer
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
BR112013002578A2 (pt) imunoglobinas de domínio variável duplo e usos das mesmas
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
EA201170158A1 (ru) Агенты, связывающиеся с рецептором notch1, и способы их применения
EA201101704A1 (ru) ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
PH12014501363A1 (en) Anticancer fusion protein
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
MX2014004132A (es) Señuelos humanos notch1.
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same